|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for SLK |
 Gene summary |
| Basic gene Info. | Gene symbol | SLK |
| Gene name | STE20-like kinase | |
| Synonyms | LOSK|STK2|bA16H23.1|se20-9 | |
| Cytomap | UCSC genome browser: 10q24.33 | |
| Type of gene | protein-coding | |
| RefGenes | NM_014720.2, | |
| Description | CTCL tumor antigen se20-9Long Ste20-like KinaseSNF1 (sucrose nonfermenting, yeast, homolog)-like kinase, SNF1 sucrose nonfermenting like kinaseSNF1 sucrose nonfermenting like kinaseSTE20-like serine/threonine-protein kinaseSTE20-related kinaseSTE20- | |
| Modification date | 20141207 | |
| dbXrefs | HGNC : HGNC | |
| Ensembl : ENSG00000065613 | ||
| HPRD : 11585 | ||
| Vega : OTTHUMG00000018999 | ||
| Protein | UniProt: Q9H2G2 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_SLK | |
| BioGPS: 9748 | ||
| Pathway | NCI Pathway Interaction Database: SLK | |
| KEGG: SLK | ||
| REACTOME: SLK | ||
| Pathway Commons: SLK | ||
| Context | iHOP: SLK | |
| ligand binding site mutation search in PubMed: SLK | ||
| UCL Cancer Institute: SLK | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0046777 | protein autophosphorylation | 18239682 |
| Top |
| Ligand binding site mutations for SLK |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | K63 | K63E | KIRC | 1 | I106 | L104I | LUAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for SLK |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | I106 | L104I | -1.0928793 | K63 | K63E | -0.26630338 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for SLK from PDB |
| Top |
| Differential gene expression and gene-gene network for SLK |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for SLK |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0236969 | Substance-Related Disorders | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for SLK |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB07664 | 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE | Small molecule |  |
| Experimental | DB07853 | [4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of SLK go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 6UI | 4-[4-(6-METHOXYNAPHTHALEN-2-YL)-1H-IMIDAZOL- 5-YL]PYRIDINE | 4usf | A | K63 I106 | 6UI | 4-[4-(6-METHOXYNAPHTHALEN-2-YL)-1H-IMIDAZOL- 5-YL]PYRIDINE | 4usf | B | K63 I106 |
| Top |
| Conservation information for LBS of SLK |
| Multiple alignments for Q9H2G2 in multiple species |
| LBS | AA sequence | # species | Species | A112 | LIEFCAGGAVD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A115 | FCAGGAVDAVM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A172 | GDIKLADFGVS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A61 | TNVLAAAKVID | 2 | Mus musculus, Rattus norvegicus | A61 | TSVLAAAKVID | 1 | Homo sapiens | C111 | ILIEFCAGGAV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D173 | DIKLADFGVSA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E109 | LWILIEFCAGG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F110 | WILIEFCAGGA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F174 | IKLADFGVSAK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F45 | LGDGAFGKVYK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G114 | EFCAGGAVDAV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I106 | ENNLWILIEFC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I108 | NLWILIEFCAG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K63 | VLAAAKVIDTK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L162 | KAGNILFTLDG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L40 | EIIGELGDGAF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L83 | VEIDILASCDH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N160 | DLKAGNILFTL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V48 | GAFGKVYKAQN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |